Flavone acetic acid enhances accumulation of IL-2 activated NK cells within established metastases

In Vivo

Volumn 12, Issue 6, 1998, Pages 593-597

  Kitson, Richard P ^a,c   Ohashi, Masami ^b   Brunson, Kenneth W ^a   Goldfarb, Ronald H ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b KANEBO LTD   (Japan)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Flavone acetic acid; Interleukin 2; NK cells metastases

Indexed keywords

INTERLEUKIN 2; MITOFLAXONE; RHODAMINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; IMAGE ANALYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA B16; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN;

EID: 0032442804     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Basse PH, Goldfarb RH, Herberman RB, Hokland ME: Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. In Vivo 8: 17-24, 1994.
2. Basse P, Herberman RB, Hokland M, Goldfarb RH: Tissue distribution of adoptively transferred adherent Iymphokirie-activated killer cells assessed by different cell labels. Cancer Immunol Immunother 34: 221-227, 1992.
3. Basse PH, Herberman RB, Hokland ME, Goldfarb RH: Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration. Nat Immun 11: 193-202, 1992.
4. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
5. Goldfarb RH, Ohashi M, Brunson KW, Kirii Y, Kotera Y, Basse PH, Kitson RP: Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Anticancer Res in press, 1998.
6. Salup RR, Wiltrout RH: Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Cancer Res 46: 3358-3363, 1986.
7. Kedar E, Ben-Aziz R, Epstein E, Leshem B: Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol Immunother 29: 74-78, 1989.
8. Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walter J, Kedar E: Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 35: 135-144, 1992.
9. Kedar E, Klein E: Cancer immunotherapy: are the results discouraging? Can they be improved?. Adv Cancer Res 59: 245-322, 1992.
10. Eggermont AM, Sugarbaker PH: Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer 58: 410-414, 1988.
11. Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, Uchino J, Kobayashi H: Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 18: 257-262, 1995.
12. Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Hornung RL: Flavone-8- acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol 140: 3261-5, 1988.
13. Zwi LJ, Baguley BC, Gavin JB, Wilson WR: Blood flow failure as a major determinant in the antitumor action of flayone acetic acid. J Natl Cancer Inst 81: 1005-13, 1989.
14. Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, Basse PH: Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy. Cancer Res 55: 4627-4632, 1995.
15. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E: Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 142: 1748-1754, 1989.
16. Bowler K, Pearson JA: Long-term effects of flavone acetic acid on the growth of a rat tumour. Anticancer Res 12: 1275-9, 1992.
17. D'Alessandro N, Borsellino N: In vivo effects of tumor necrosis factor-alpha or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma. Anticancer Drugs 7: 281-7, 1996.
18. Goldfarb RH, Kitson RP, Brunson KW, Yoshino K, Hirota N, Kotera Y, Kirii Y, Ohashi MA: Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles. FASEB J 12: A475, 1998.